{"id":"NCT02586025","sponsor":"Hoffmann-La Roche","briefTitle":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","officialTitle":"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy After Surgery and Chemotherapy in Patients With Early-Stage or Locally Advanced HER2-Positive Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-14","primaryCompletion":"2017-10-23","completion":"2022-03-14","firstPosted":"2015-10-26","resultsPosted":"2019-01-03","lastUpdate":"2023-05-22"},"enrollment":329,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"FEC Chemotherapy","otherNames":[]},{"type":"PROCEDURE","name":"Surgery","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":["RO4368451"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Trastuzumab","otherNames":["RO0452317"]}],"arms":[{"label":"Trastuzumab, Pertuzumab, and Chemotherapy","type":"EXPERIMENTAL"},{"label":"Trastuzumab, Placebo, and Chemotherapy","type":"EXPERIMENTAL"}],"summary":"This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-na√Øve participants with early-stage or locally advanced HER2-positive breast cancer. The anticipated treatment duration is approximately 17 months.","primaryOutcome":{"measure":"Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)","timeFrame":"At surgery (Cycle 4 Days 22-35)","effectByArm":[{"arm":"Pertuzumab, Trastuzumab, and Chemotherapy","deltaMin":39.3,"sd":null},{"arm":"Placebo, Trastuzumab, and Chemotherapy","deltaMin":21.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0014"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":23,"countries":["China","South Korea","Taiwan","Thailand"]},"refs":{"pmids":["31647503"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":218},"commonTop":["Neutropenia","Leukopenia","Alopecia","Nausea","Anaemia"]}}